NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Xeltis announces FDA Breakthrough Device Designation for aXessTM and first patient treated in US pivotal trial<
14 Nov 2024

Xeltis announces FDA Breakthrough Device Designation for aXessTM and first patient treated in US pivotal trial

Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages over current therapies
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights<
12 Nov 2024

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

Strong Cash Position Expected to Support Operations into 2H 2026
VarmX announces appointment of John Glasspool as CEO<
12 Nov 2024

VarmX announces appointment of John Glasspool as CEO

Leadership team fully strengthened to drive next phase of development
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update<
11 Nov 2024

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Two pivotal trials fully enrolled and on track to deliver topline data during the first half of 2025.
Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development<
05 Nov 2024

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development

Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs
Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer<
04 Nov 2024

Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer

Frits is an industry veteran with a proven track record in nephrology drug development
Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes<
04 Nov 2024

Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes

The Phase 2 study will evaluate the efficacy, safety and tolerability of the company’s lead lipidated IL-22 analogue, CK-0045, in patients with obesity and type 2 diabetes
Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients<
01 Nov 2024

Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients

Topline data expected in mid-2025
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension<
30 Oct 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

Topline data now anticipated in mid first half of 2025 
MedLumics new CEO and Board Member announces 10 patients treated in First in Man (FIM) clinical trial with the real-time visually guided AblaView PFA System.<
29 Oct 2024

MedLumics new CEO and Board Member announces 10 patients treated in First in Man (FIM) clinical trial with the real-time visually guided AblaView PFA System.

MedLumics officially enters the clinical development phase with its AblaView catheter and control console with PF generator

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.